NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts
NCT02599324 2023-11-18Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsPharmacyclics LLC.Phase 1/2 Completed263 enrolled 34 charts
NCT01282463 2019-09-09Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaEli Lilly and CompanyPhase 2 Completed148 enrolled 19 charts